Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STX-1600
- Development stage
- Preclinical
- Lead developer
- Scribe Therapeutics
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Classical Binding Small Molecules → Small Molecules, Gene Silencing → Gene Therapies, Covalent Small Molecules → Small Molecules, Gene Addition/Replacement → Gene Therapies
01
Overview
STX-1600 is an investigational epigenetic silencing therapy being developed by Scribe Therapeutics for the treatment of cardiovascular disease associated with elevated levels of Lipoprotein(a) [Lp(a)]. The drug utilizes Scribe's proprietary ELXR platform, which employs CRISPR-based technology to achieve durable, long-term silencing of the *LPA* gene without introducing double-stranded DNA breaks. By targeting the hepatic expression of the *LPA* gene, STX-1600 aims to reduce the synthesis and circulating levels of Lp(a), a genetically determined and independent risk factor for atherosclerosis, myocardial infarction, and calcific aortic valve stenosis. It is currently in the preclinical stage of development.
Beyond the preview
Go deeper on STX-1600.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STX-1600.